Aim: Aim of this study was to evaluate the effect of anakinra (ANK) addition to remdesivir
(RDV) on all-cause 28-day mortality in patients hospitalized with COVID-19. Patients & …

Intro The unavailability of specific treatment for COVID-19 prompted the empirical use of
remdesivir, a viral RNA polymerase inhibitor. Since evidences present conflicting results …

Background: This study aimed to determine the real-world safety and effectiveness of
remdesivir in hospitalized adult COVID-19 patients with moderate-to-critical disease in …

Objectives: Remdesivir is currently approved for the treatment of COVID-19. The
recommendation for using remdesivir in patients with COVID-19 was based on the in vitro …

Methods In this single-center, retrospective study, we evaluated data of patients hospitalized
for COVID-19 pneumonia at the Lüdenscheid Clinic in Germany from January 1, 2020, to …

Purpose: To evaluate the safety and efficacy of remdesivir in adult patients with COVID-19.
Methods: PubMed, Embase, Scopus, Web of Science, Cochrane Library, ClinicalTrials. gov …

Background No specific antiviral drug has been proven effective for treatment of patients
with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside …

Background Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro
and efficacy in animal models of coronavirus disease 2019 (Covid-19). Methods We …

Background Remdesivir (RDV) in coronavirus disease 2019 (COVID-19) has been found to
be beneficial in patients with severe disease; however, its role in mild-moderate disease and …

Introduction During the early phase of the coronavirus disease 2019 (COVID‐19), remdesivir
was only approved for hospitalized patients. Our institution developed hospital‐based …